Dermatology Products · LP-087
Acyclovir Cream
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-087Dermatology Products
- Generic identity
- AcyclovirCream
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-087
- Generic identity
- Acyclovir
- Presentation
- Cream
- Catalogue strength
- 5%
- Catalogue pack
- Tube 5 g / 10 g
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: acyclovir.
- Dosage form: cream.
- Catalogue concentration: 5%.
- Catalogue tube options: 5 g and 10 g.
Layer 02 · Unresolved product-specific fields
- Exact cream base/excipients, preservative system and container-closure.
- Approved topical site(s), indication, age eligibility and application instructions.
- Whether both tube sizes are controlled/registered SKUs.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 5% | Cream | — | Tube 5 g | Topical label, formula and SKU evidence not supplied. |
| B | 5% | Cream | — | Tube 10 g | Topical label, formula and SKU evidence not supplied. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Acyclovir, also spelled aciclovir, is an antiviral that can be formulated as a skin cream for selected localized herpes-virus infections. A topical cream has a different role from oral or ophthalmic acyclovir and should not inherit their indications. This educational ingredient profile does not establish Luang Pharma approved labeling, claim eradication of latent infection or suggest that treatment prevents transmission.
Clinical context and therapeutic role
A clinician or pharmacist should confirm that the lesions fit the authorized topical indication and identify situations needing a different approach. Eye symptoms, extensive lesions, severe illness or immunosuppression warrant prompt assessment. Recurrent lesions may require a broader diagnostic and management discussion. A skin cream should not be placed in the eye or used internally, and its availability in a catalogue does not establish suitability for genital or other sensitive sites.
Selected safety context
Local burning, stinging, dryness or irritation can occur. A worsening rash or swelling may indicate hypersensitivity and needs review. Keep a skin preparation away from the eyes and do not apply it to an unapproved site. Avoid transferring infection through contact with lesions or shared applicators. Severe allergy, spreading infection, eye pain, visual symptoms or failure to improve warrants assessment. The actual label determines age restrictions and permitted application sites.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies a skin cream. The cream base, preservatives, excipients and suitability for particular sites require confirmation from product information. A concentration does not establish equivalence to a vaginal, oral, ophthalmic or injectable preparation containing the same ingredient. Authorized application instructions remain product-specific.
Keep the tube or container labeled, close it after use and avoid contaminating the contents. Follow the actual label for application sites, storage and expiry. Do not transfer another product’s instructions on dressings, sensitive areas or duration to this proposed presentation.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should confirm the skin diagnosis, application site, extent and suitability of the exact formulation. Unexplained, spreading or recurrent lesions need assessment. Product-specific instructions determine age restrictions, handling and permitted use.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product cream specification/formula.
Approved topical label/leaflet for the intended jurisdiction.
Tube/container-closure specification and size-to-SKU matrix.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: AciclovirArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 23 February 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-087.
Professional enquiries
Request product-specific evidence for LP-087.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.